Presynaptic control of serotonin on striatal dopamine function.
Identifieur interne : 000877 ( PubMed/Checkpoint ); précédent : 000876; suivant : 000878Presynaptic control of serotonin on striatal dopamine function.
Auteurs : Sylvia Navailles [France] ; Philippe De DeurwaerdèreSource :
- Psychopharmacology [ 1432-2072 ] ; 2011.
English descriptors
- KwdEn :
- Animals, Corpus Striatum (metabolism), Dopamine (metabolism), Humans, Neurons (metabolism), Parkinson Disease (physiopathology), Presynaptic Terminals (metabolism), Receptors, Serotonin (metabolism), Schizophrenia (physiopathology), Serotonin (metabolism), Serotonin Antagonists (pharmacology), Serotonin Receptor Agonists (pharmacology).
- MESH :
- chemical , metabolism : Dopamine, Receptors, Serotonin, Serotonin.
- metabolism : Corpus Striatum, Neurons, Presynaptic Terminals.
- chemical , pharmacology : Serotonin Antagonists, Serotonin Receptor Agonists.
- physiopathology : Parkinson Disease, Schizophrenia.
- Animals, Humans.
Abstract
The influences of the serotonergic system on dopamine (DA) neuron activity have received considerable attention during the last three decades due to the real opportunity to improve disorders related to central DA neuron dysfunctions such as Parkinson's disease, schizophrenia, or drug abuse with serotonergic drugs. Numerous biochemical and behavioral data indicate that serotonin (5-HT) affects dopaminergic terminal function in the striatum.
DOI: 10.1007/s00213-010-2029-y
PubMed: 20953589
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20953589Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Presynaptic control of serotonin on striatal dopamine function.</title><author><name sortKey="Navailles, Sylvia" sort="Navailles, Sylvia" uniqKey="Navailles S" first="Sylvia" last="Navailles">Sylvia Navailles</name><affiliation wicri:level="3"><nlm:affiliation>Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227, Université Victor Segalen Bordeaux 2, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227, Université Victor Segalen Bordeaux 2, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdère">Philippe De Deurwaerdère</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:20953589</idno><idno type="pmid">20953589</idno><idno type="doi">10.1007/s00213-010-2029-y</idno><idno type="wicri:Area/PubMed/Corpus">000A06</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A06</idno><idno type="wicri:Area/PubMed/Curation">000966</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000966</idno><idno type="wicri:Area/PubMed/Checkpoint">000966</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000966</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Presynaptic control of serotonin on striatal dopamine function.</title><author><name sortKey="Navailles, Sylvia" sort="Navailles, Sylvia" uniqKey="Navailles S" first="Sylvia" last="Navailles">Sylvia Navailles</name><affiliation wicri:level="3"><nlm:affiliation>Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227, Université Victor Segalen Bordeaux 2, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227, Université Victor Segalen Bordeaux 2, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdère">Philippe De Deurwaerdère</name></author></analytic><series><title level="j">Psychopharmacology</title><idno type="eISSN">1432-2072</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Corpus Striatum (metabolism)</term><term>Dopamine (metabolism)</term><term>Humans</term><term>Neurons (metabolism)</term><term>Parkinson Disease (physiopathology)</term><term>Presynaptic Terminals (metabolism)</term><term>Receptors, Serotonin (metabolism)</term><term>Schizophrenia (physiopathology)</term><term>Serotonin (metabolism)</term><term>Serotonin Antagonists (pharmacology)</term><term>Serotonin Receptor Agonists (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Receptors, Serotonin</term><term>Serotonin</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Neurons</term><term>Presynaptic Terminals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Serotonin Antagonists</term><term>Serotonin Receptor Agonists</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term><term>Schizophrenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The influences of the serotonergic system on dopamine (DA) neuron activity have received considerable attention during the last three decades due to the real opportunity to improve disorders related to central DA neuron dysfunctions such as Parkinson's disease, schizophrenia, or drug abuse with serotonergic drugs. Numerous biochemical and behavioral data indicate that serotonin (5-HT) affects dopaminergic terminal function in the striatum.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20953589</PMID><DateCreated><Year>2011</Year><Month>02</Month><Day>02</Day></DateCreated><DateCompleted><Year>2011</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2072</ISSN><JournalIssue CitedMedium="Internet"><Volume>213</Volume><Issue>2-3</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl.)</ISOAbbreviation></Journal><ArticleTitle>Presynaptic control of serotonin on striatal dopamine function.</ArticleTitle><Pagination><MedlinePgn>213-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00213-010-2029-y</ELocationID><Abstract><AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">The influences of the serotonergic system on dopamine (DA) neuron activity have received considerable attention during the last three decades due to the real opportunity to improve disorders related to central DA neuron dysfunctions such as Parkinson's disease, schizophrenia, or drug abuse with serotonergic drugs. Numerous biochemical and behavioral data indicate that serotonin (5-HT) affects dopaminergic terminal function in the striatum.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors propose a thorough examination of data showing controversial effects induced by striatal 5-HT on dopaminergic activity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Inhibitory and excitatory effects of exogenous 5-HT have been reported on DA release and synthesis, involving various striatal 5-HT receptors. 5-HT also promotes an efflux of DA through reversal of the direction of DA transport. By analogy with the mechanism of action described for amphetamine, the consequences of 5-HT entering DA terminals might explain both the excitatory and inhibitory effects of 5-HT on presynaptic DA terminal activity, but the physiological relevance of this mechanism is far from clear. The recent data suggest that the endogenous 5-HT system affects striatal DA release in a state-dependent manner associated with the conditional involvement of various 5-HT receptors such as 5-HT(2A), 5-HT(2C), 5-HT(3), and 5-HT(4) receptors.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Methodological and pharmacological issues have prevented a comprehensive overview of the influence of 5-HT on striatal DA activity. The distribution of striatal 5-HT receptors and their restricted influence on DA neuron activity suggest that the endogenous 5-HT system exerts multiple and subtle influences on DA-mediated behaviors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Navailles</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227, Université Victor Segalen Bordeaux 2, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Deurwaerdère</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012702">Serotonin Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017366">Serotonin Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012702" MajorTopicYN="N">Serotonin Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017366" MajorTopicYN="N">Serotonin Receptor Agonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20953589</ArticleId><ArticleId IdType="doi">10.1007/s00213-010-2029-y</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><noCountry><name sortKey="De Deurwaerdere, Philippe" sort="De Deurwaerdere, Philippe" uniqKey="De Deurwaerdere P" first="Philippe" last="De Deurwaerdère">Philippe De Deurwaerdère</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Navailles, Sylvia" sort="Navailles, Sylvia" uniqKey="Navailles S" first="Sylvia" last="Navailles">Sylvia Navailles</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000877 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000877 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:20953589
|texte= Presynaptic control of serotonin on striatal dopamine function.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20953589" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |